Incyte (INCY) Competitors $68.44 -0.30 (-0.43%) As of 12:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ALNY, BIIB, UTHR, NBIX, EXEL, BMRN, EXAS, RGEN, HALO, and MDGLShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Incyte vs. Its Competitors Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Incyte (NASDAQ:INCY) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability. Do analysts rate INCY or ALNY? Incyte presently has a consensus price target of $74.53, indicating a potential upside of 8.76%. Alnylam Pharmaceuticals has a consensus price target of $340.00, indicating a potential upside of 4.89%. Given Incyte's higher possible upside, equities analysts clearly believe Incyte is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incyte 1 Sell rating(s) 12 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.22Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.79 Do institutionals & insiders have more ownership in INCY or ALNY? 97.0% of Incyte shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 17.8% of Incyte shares are held by company insiders. Comparatively, 1.2% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, INCY or ALNY? Incyte has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Which has stronger valuation and earnings, INCY or ALNY? Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIncyte$4.24B3.13$32.62M$0.32214.16Alnylam Pharmaceuticals$2.25B18.80-$278.16M-$2.09-155.10 Is INCY or ALNY more profitable? Incyte has a net margin of 0.48% compared to Alnylam Pharmaceuticals' net margin of -11.49%. Incyte's return on equity of 2.77% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Incyte0.48% 2.77% 1.77% Alnylam Pharmaceuticals -11.49%-510.31%-6.48% Does the media favor INCY or ALNY? In the previous week, Incyte had 4 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for Incyte and 25 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.02 beat Incyte's score of 0.55 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 11 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Alnylam Pharmaceuticals 14 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryIncyte beats Alnylam Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.27B$2.90B$5.51B$8.92BDividend YieldN/A2.69%5.38%4.12%P/E Ratio214.2021.4026.2119.84Price / Sales3.13279.63415.30113.63Price / Cash123.0141.8936.4957.06Price / Book3.837.358.005.32Net Income$32.62M-$55.05M$3.15B$248.42M7 Day Performance1.45%2.02%1.72%2.50%1 Month Performance4.93%6.76%4.63%5.53%1 Year Performance16.12%4.83%35.87%19.65% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.3621 of 5 stars$68.44-0.4%$74.53+8.9%+12.9%$13.25B$4.24B213.842,617ALNYAlnylam Pharmaceuticals4.2833 of 5 stars$313.13+1.1%$319.58+2.1%+32.4%$40.83B$2.25B-149.822,230Analyst ForecastBIIBBiogen4.9742 of 5 stars$124.76-1.8%$188.19+50.8%-43.9%$18.28B$9.68B12.327,605UTHRUnited Therapeutics4.9941 of 5 stars$286.39-1.5%$393.08+37.3%-8.8%$12.92B$2.88B11.431,305Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.7737 of 5 stars$125.80-0.6%$162.00+28.8%-8.6%$12.45B$2.36B42.641,800Positive NewsEXELExelixis4.7384 of 5 stars$43.37+7.4%$41.00-5.5%+96.0%$11.83B$2.17B19.711,147Positive NewsAnalyst ForecastHigh Trading VolumeBMRNBioMarin Pharmaceutical4.9447 of 5 stars$54.08-1.7%$93.45+72.8%-31.6%$10.37B$2.95B20.103,040Positive NewsEXASExact Sciences4.8821 of 5 stars$52.54-0.9%$70.90+34.9%+28.7%$9.91B$2.76B-9.547,000Positive NewsAnalyst RevisionRGENRepligen4.7966 of 5 stars$120.11+1.1%$173.25+44.2%+2.5%$6.75B$634.44M-266.911,778Positive NewsAnalyst DowngradeHALOHalozyme Therapeutics4.8482 of 5 stars$52.800.0%$61.90+17.2%+1.7%$6.51B$1.02B14.04390Analyst RevisionMDGLMadrigal Pharmaceuticals3.9676 of 5 stars$282.99-1.0%$420.63+48.6%+7.5%$6.28B$180.13M-15.6890 Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
